SELLAS Life Sciences Group Inc
SLS
Market Cap$81.06M
Close$
$0.02
98.8% downside
Current Fair Value
98.8% downsideOvervalued by 98.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $81.06 Million |
|---|---|
| Enterprise Value | $56.40 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.34 |
| Beta | 2.39 |
| Outstanding Shares | 57,630,506 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.11 |
|---|---|
| PEG | 18.12 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.27 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About SELLAS Life Sciences Group Inc
7 employeesSELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Ketteri...